NCT00700128View on ClinicalTrials.gov

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
MigrainesBleedingSpotting
Interventions
DRUG

frovatriptan

Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.

DRUG

frovatriptan

frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.

DRUG

placebo

placebo

Trial Locations (1)

76508

Scott & White Memorial Hospital, Temple

Sponsors

Collaborators (1)

Endo Pharmaceuticals
All Listed Sponsors
collaborator

Endo Pharmaceuticals

INDUSTRY

lead

Scott and White Hospital & Clinic

OTHER